The New England Journal of Medicine3d
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 ...
The New England Journal of Medicine3d
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
We enrolled patients 50 years of age or older with type 2 diabetes, elevated systolic blood pressure, and an increased risk of cardiovascular disease at 145 clinical sites across China. Patients ...
The New England Journal of Medicine3d
Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia
Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular ...
The New England Journal of Medicine3d
Left Atrial Appendage Closure after Ablation for Atrial Fibrillation
A total of 803 patients were assigned to undergo left atrial appendage closure, and 797 to receive anticoagulant therapy. The mean (±SD) age of the patients was 69.6±7.7 years, 34.1% of the ...
The New England Journal of Medicine3d
NEJM at AHA — Left Atrial Appendage Closure after Ablation for Atrial Fibrillation
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.
The New England Journal of Medicine3d
NEJM at AHA — Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.
The New England Journal of Medicine3d
NEJM at AHA — CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.
The New England Journal of Medicine3d
NEJM at AHA — Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.
The New England Journal of Medicine3d
NEJM at AHA — Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.
The New England Journal of Medicine3d
Mind the Sentinel — Applying Patient-Safety Paradigms to Clinician Well-Being
To uncover latent hazards to clinician well-being, health care organizations can adapt lessons from the patient-safety movement and treat clinicians’ psychological ill health as preventable harm.
The New England Journal of Medicine3d
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly ...
The New England Journal of Medicine5d
Inebilizumab for Treatment of IgG4-Related Disease
IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for ...